← Eichor
Condition: Cervical Neuroendocrine Carcinoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Cervical Neuroendocrine Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

An International Study on Pediatric Patients With Rare Tumors.
Phase N/A · 1 location(s) · Azienda Ospedaliera di Padova · NCT07072143BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or S
Phase 2 · 225 location(s) · National Cancer Institute (NCI) · NCT05136196At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Phase 2 · 2 location(s) · Mayo Clinic · NCT05969860A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 · 12 location(s) · MacroGenics · NCT06242470Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Phase 1/Phase 2 · 2 location(s) · University of Arizona · NCT06814496Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine
Phase 2 · 1 location(s) · Chang Gung Memorial Hospital · NCT07336147Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tu
Phase 2 · 1 location(s) · Vall d'Hebron Institute of Oncology · NCT06630611Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease
Phase 2 · 4 location(s) · CNAO National Center of Oncological Hadrontherapy · NCT05229614A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembroliz
Phase 1/Phase 2 · 9 location(s) · ImmVira Pharma Co. Ltd · NCT04370587A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malign
Phase 1/Phase 2 · 13 location(s) · GV20 Therapeutics · NCT05669430A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangement
Phase 1/Phase 2 · 165 location(s) · Turning Point Therapeutics, Inc. · NCT03093116SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Phase N/A · 68 location(s) · Massive Bio, Inc. · NCT03452774Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Phase 1/Phase 2 · 6 location(s) · Simcha IL-18, Inc. · NCT04787042Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
NA · 1 location(s) · Jessica Mezzanotte Sharpe · NCT07555210Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME T
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT04693377A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05859074A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With C
Phase 1 · 41 location(s) · Genentech, Inc. · NCT05581004A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors
Phase 1 · 1 location(s) · Suzhou BlueHorse Therapeutics Co., Ltd. · NCT05366478DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cance
Phase 2/Phase 3 · 16 location(s) · Cancer Research UK · NCT05768178DESTINY-PANTUMOUR04
Phase N/A · 18 location(s) · AstraZeneca · NCT07124000A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
Phase 1 · 40 location(s) · Pfizer · NCT05355701The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr
Phase 2 · 1 location(s) · Mayo Clinic · NCT07285044Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
NA · 13 location(s) · European Organisation for Research and Treatment of Cancer - · NCT04498767Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advance
Phase 1/Phase 2 · 4 location(s) · CJ Bioscience, Inc. · NCT05877430Quantifying Systemic Immunosuppression to Personalize Cancer Therapy
Phase N/A · 1 location(s) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · NCT05621837GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamou
Phase 2 · 1 location(s) · Providence Health & Services · NCT05913388RAPA-201 Therapy of Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Rapa Therapeutics LLC · NCT05144698Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab fo
Phase 1 · 1 location(s) · LG Chem · NCT06332755A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients
Phase 1 · 16 location(s) · OncoNano Medicine, Inc. · NCT06022029DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Phase 2 · 37 location(s) · DualityBio Inc. · NCT06953089
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.